A phase I trial of combination of Vicinium and durvalumab in patients with high-grade non-muscle invasive bladder cancer (NMIBC).

Trial Profile

A phase I trial of combination of Vicinium and durvalumab in patients with high-grade non-muscle invasive bladder cancer (NMIBC).

Planning
Phase of Trial: Phase I

Latest Information Update: 13 Jun 2017

At a glance

  • Drugs Durvalumab (Primary) ; Oportuzumab monatox (Primary)
  • Indications Bladder cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 13 Jun 2017 New trial record
    • 06 Jun 2017 According to an Eleven Biotherapeutics media release, principal investigator Dr. Piyush Agarwal of the NCI Center for Cancer Research, Urologic Oncology Branch, will conduct
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top